Skip to content Skip to footer
Subscribe Now
Insights+ Key Biosimilars Events of March 2023
INSIGHTS+

Insights+ Key Biosimilars Events of March 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Biogen launched Byooviz (biosimilar, ranibizumab) for…
April 5, 2023

Read more

VIEWPOINTS_Itamar Kandel_2023
VIEWPOINTS

Itamar Kandel, CEO of Vista.ai Shares his Views on its Commercial Agreement with Siemens Healthineers for AI-Driven MRI Scanners

Shots: Itamar gave a brief overview of Vista.ai’s agreement with Siemens Healthineers to co-market a new product that brings MRI scan sequences into one automated exam protocol He elaborated on how Vista.ai’s One Click MRI acquisition  software reduces cardiac MRI (CMR) exam times, simplifies workflows, and improves image consistency The interview shows how Vista.ai is utilizing the…
April 4, 2023

Read more

VIEWPOINTS_Scott Stout_2023
VIEWPOINTS

Scott Stout, CEO of MedVector his Views on the Misunderstood FDA’s Guidance on DCTs at 2023 J.P. Morgan Healthcare Conferences

Shots:  Scott gave a brief about the MedVector and shared his personal experience from his treatment of arthritis by participating in the clinical trial  He also elaborated on how MedVector clarified the misunderstanding on FDA’s guidance on DCTs by the clinical research industry at the 41st Annual J.P. Morgan Health Care Conference 2023  The interview…
March 30, 2023

Read more

Insights+: EMA Marketing Authorization of New Drugs in February 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…
March 23, 2023

Read more

VIEWPOINTS_Craig Thompson_2023
VIEWPOINTS

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:   Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease  He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…
March 20, 2023

Read more

VIEWPOINTS_Andrea Mugan1_2023
VIEWPOINTS

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights from the Launch of Digital Patient Support Resource for Ovarian Cancer Patients

Shots:  Andrea talked about the launch of a digital patient support resource by the Ovarian Cancer Commitment (OCC) in co-development with AstraZeneca and other organizations for ovarian cancer patients  She also highlighted how this important resource, named Olivia supports in navigating ovarian cancer diagnosis. This tool is an interactive tool that allows users to access…
March 16, 2023

Read more

Disease of the Month: IgA Nephropathy
INSIGHTS+

Disease of the Month: IgA Nephropathy

Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures PharmaShots brings this month an informative take on the disease IgA nephropathy Often known as…
March 13, 2023

Read more

Load more